Display options
Cite
Guarnieri M, Tyler BM, Detolla L, et al. Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. J Pharm Bioallied Sci. 2014;6(1):38-42doi: 10.4103/0975-7406.124315.
Guarnieri, M., Tyler, B. M., Detolla, L., Zhao, M., & Kobrin, B. (2014). Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. Journal of pharmacy & bioallied sciences, 6(1), 38-42. https://doi.org/10.4103/0975-7406.124315
Guarnieri, Michael, et al. "Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs." Journal of pharmacy & bioallied sciences vol. 6,1 (2014): 38-42. doi: https://doi.org/10.4103/0975-7406.124315
Guarnieri M, Tyler BM, Detolla L, Zhao M, Kobrin B. Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315. PMID: 24459402; PMCID: PMC3895292.
Copy Download .nbib Format: NLM
Share it on

J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315.

Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

Journal of pharmacy & bioallied sciences

Michael Guarnieri, Betty M Tyler, Louis Detolla, Ming Zhao, Barry Kobrin

Affiliations

  1. Department of Neurological Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  2. Department of Pathology and Medicine, School of Medicine, Division of Infectious Diseases and Public Health, The Program of Comparative Medicine, University of Maryland, Baltimore, Maryland, USA.
  3. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

PMID: 24459402 PMCID: PMC3895292 DOI: 10.4103/0975-7406.124315

Abstract

BACKGROUND: Long-acting therapy in laboratory animals offers advantages over the current practice of 2-3 daily drug injections. Yet little is known about the disintegration of biodegradable drug implants in rodents.

OBJECTIVE: Compare bioavailability of buprenorphine with the biodegradation of lipid-encapsulated subcutaneous drug pellets.

METHODS: Pharmacokinetic and histopathology studies were conducted in BALB/c female mice implanted with cholesterol-buprenorphine drug pellets.

RESULTS: Drug levels are below the level of detection (0.5 ng/mL plasma) within 4-5 days of implant. However, necroscopy revealed that interstitial tissues begin to seal implants within a week. Visual inspection of the implant site revealed no evidence of inflammation or edema associated with the cholesterol-drug residue. Chemical analyses demonstrated that the residues contained 10-13% of the initial opiate dose for at least two weeks post implant.

DISCUSSION: The results demonstrate that biodegradable scaffolds can become sequestered in the subcutaneous space.

CONCLUSION: Drug implants can retain significant and unintended reservoirs of drugs.

Keywords: Analgesia; buprenorphine; disintegration; mouse; sustained delivery

References

  1. J Anal Toxicol. 2003 Mar;27(2):103-5 - PubMed
  2. J Biomed Mater Res A. 2005 Oct 1;75(1):185-91 - PubMed
  3. Drug Dev Ind Pharm. 1999 Jun;25(6):773-9 - PubMed
  4. Pharmacol Biochem Behav. 1983 Mar;18(3):471-4 - PubMed
  5. Drug Deliv Transl Res. 2012 Aug;2(4):238-53 - PubMed
  6. Anesth Analg. 1994 Oct;79(4):706-9 - PubMed
  7. Comp Med. 2003 Jun;53(3):280-7 - PubMed
  8. Lab Anim (NY). 2010 Aug;39(8):236-40 - PubMed
  9. Contemp Top Lab Anim Sci. 2000 Mar;39(2):8-13 - PubMed
  10. Lab Anim. 2002 Jul;36(3):322-43 - PubMed
  11. J Am Assoc Lab Anim Sci. 2012 May;51(3):322-8 - PubMed
  12. Lab Anim (NY). 2012 Nov;41(11):337-43 - PubMed
  13. J Am Assoc Lab Anim Sci. 2012 May;51(3):311-21 - PubMed
  14. J Pharm Pharmacol. 2006 Mar;58(3):295-302 - PubMed
  15. Acta Neurochir (Wien). 2010 Nov;152(11):1923-31 - PubMed

Publication Types

Grant support